Advertisement
Table 1 Clinical history of the patient together with diagnostic results and treatment
| Visit No. | Date | Methods | Hematologic parameters | Treatment | Results |
|---|---|---|---|---|---|
| 1 | August 2003 | GTG, FISH (WCP probes) | WBC 327×109/l with 73% neutrophils, 23% lymphocytes, 3% monocytes and 1% eosinophiles. Hgb 11.9 g/dl and Plts 540×109/l. | - | 46,XX,t(9;22)[20] |
| 2 | November 2005 | GTG, FISH (BCR/ABL and WCP probes) | WBC 7.9×109/l with 66% neutrophils, 31% lymphocytes, 2% monocytes and 1% eosinophiles. Hgb 11.2 g/dl and Plts 371×109/l. | Imatinib mesylate at 200 mg/day for overall 12 months | 46,XX,t(9;22)[20] |
| 3 | November 2006 | GTG, FISH (BCR/ABL probe) | WBC 6.8×109/l with 64% neutrophils, 33% lymphocytes, 2% monocytes and 1% eosinophiles. Hgb 12.8 g/dl and Plts 305×109/l. | Imatinib at 400 mg/day for overall 12 months | 46,XX,t(9;22)[20] |
| 4 | November 2008; patients interrupted treatment for ~12 months; Nitolib was initiated November 2009 | GTG, FISH, RT-PCR, RFLP | WBC 15.5×109/l with 54% neutrophils, 43% lymphocytes, 3% monocytes and 1% eosinophiles. Hgb 8.8 g/dl and Plts 215×109/l. | Imatinib at 400 mg/day for overall 12 months in the total. | 45,XX,t(9;22),+dic(17;18),-17,-18[20] |
| b2a2 transcript | |||||
| T315I mutation | |||||
| 5 | March 2010 | GTG, FISH, RT-PCR, RFLP | WBC 2.2×109/l with 25% neutrophils, 73% lymphocytes, 1% monocytes and 1% eosinophiles. Hgb 9.5 g/dl and Plts 111x109/l. | nilotinib at 800 mg/day for overall 5 months. | 45,XX,t(9;22),+dic(17;18),-17,-18 [16]/46,XX,t(9;22)[4] |
| co-expression of b2a2 and b3a2 transcript. | |||||
| T315I mutation | |||||
| 6 | November 2010 | The patient passed away under the treatment due to unknown reasons | |||
